PMID- 28901478
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20180606
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 5
DP  - 2017 Nov
TI  - MicroRNA‑195 inhibits cell proliferation, migration and invasion in laryngeal 
      squamous cell carcinoma by targeting ROCK1.
PG  - 7154-7162
LID - 10.3892/mmr.2017.7460 [doi]
AB  - Laryngeal carcinoma is the second most common malignancy of the head and neck 
      cancers. The most common type of laryngeal carcinoma comprises laryngeal squamous 
      cell carcinoma (LSCC), which accounts for ~95% of laryngeal carcinoma cases. 
      Despite great progress in diagnostic and therapeutic techniques over the last few 
      decades, the prognosis for patients with LSCC remains poor. A number of studies 
      reported that various miRNAs are dysregulated in LSCC and serve critical roles in 
      LSCC tumorigenesis and tumor development. The present study aimed to evaluate the 
      expression level of microRNA (miR)‑195 and its possible roles in LSCC. Briefly, 
      miR‑195 was downregulated in LSCC tissues and cell lines. In addition, low 
      miR‑195 expression was significantly correlated with lymph node metastasis and 
      TNM stage of LSCC patients. Further study has demonstrated that miR‑195 
      overexpression suppressed cell proliferation, migration and invasion of LSCC. 
      Moreover, rho‑associated kinase 1 (ROCK1) was identified as a direct target gene 
      of miR‑195. Downregulation of ROCK1 exerted similar roles to that of miR‑195 
      overexpression in LSCC, suggesting ROCK1 was a direct downstream target of 
      miR‑195. These findings elucidated a novel molecular mechanism for the pathogenic 
      mechanism in LSCC carcinogenesis and progression, and may have a potential role 
      in the treatment of patients with LSCC.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Otolaryngology, Head and Neck Surgery, Tianjin Union Medical 
      Center, Tianjin 300121, P.R. China.
FAU - Liu, Jixiang
AU  - Liu J
AD  - Department of Otolaryngology, Head and Neck Surgery, Tianjin Union Medical 
      Center, Tianjin 300121, P.R. China.
FAU - Wang, Lin
AU  - Wang L
AD  - Department of Otolaryngology, Head and Neck Surgery, Tianjin Union Medical 
      Center, Tianjin 300121, P.R. China.
FAU - Yang, Xiangli
AU  - Yang X
AD  - Department of Otolaryngology, Head and Neck Surgery, Tianjin Union Medical 
      Center, Tianjin 300121, P.R. China.
FAU - Liu, Xiang
AU  - Liu X
AD  - Department of Otolaryngology, Head and Neck Surgery, Tianjin Union Medical 
      Center, Tianjin 300121, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170911
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Antagomirs)
RN  - 0 (MIRN195 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.11.1 (ROCK1 protein, human)
RN  - EC 2.7.11.1 (rho-Associated Kinases)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Aged
MH  - Antagomirs/metabolism
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/genetics/metabolism/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - *Cell Proliferation
MH  - Down-Regulation
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/metabolism/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - MicroRNAs/antagonists & inhibitors/genetics/*metabolism
MH  - Middle Aged
MH  - RNA Interference
MH  - RNA, Small Interfering/metabolism
MH  - Sequence Alignment
MH  - rho-Associated Kinases/antagonists & inhibitors/genetics/*metabolism
EDAT- 2017/09/14 06:00
MHDA- 2018/06/07 06:00
CRDT- 2017/09/14 06:00
PHST- 2016/07/19 00:00 [received]
PHST- 2017/07/20 00:00 [accepted]
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
PHST- 2017/09/14 06:00 [entrez]
AID - 10.3892/mmr.2017.7460 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Nov;16(5):7154-7162. doi: 10.3892/mmr.2017.7460. Epub 2017 Sep 
      11.